OSTEOPOROSIS PADA HIPERTIROIDISME
Abstract
Abstract. Osteoporosis didefenisikan sebagai pengurangan masa dan kekuatan tulang sehingga meningkatakan risiko fraktur. Di Amerika serikat, terjadi pada 1 dari 2 wanita usia lebih dari 50 tahun dan meningkat sejalan dengan bertambahnya usia, mengakibatkan fraktur, meningkatkan morbiditas serta mortalitas.Hipertiroidisme mencetuskan bone turnover dan mempersingkat siklus remodelling tulang normal dan lebih sering merusak tulang kortikal (hip dan forearm) dibanding tulang trabekular (spine).Hypertiroidisme berkaitan dengan remodelling tulang, menurunnya densitas tulang, osteoporosis dan meningkatnya kejadian fraktur. Konsentrasi hormon tiroid yang tinggi dalam jangka waktu lama meningkatkan risiko osteoporosis dan risiko fraktur. Perubahan metabolisme tulang berkaitan dengan keseimbangan kalsium negatif, hiperkalsiuria dan kadang-kadang hiperkalsemia. Penanganan terhadap hipertiroidisme akan mengembalikan densitas tulang.
Abstract. Osteoporosis is defined as low bone mass density that increase fractur risk. In US, 0steoporosis affecting approximately 1 of 2 old women and increase fractur risk, morbidity and mortality.Hipertiroidisme causes bone turnover and stimullates bone remodelling cycle, cortikal (hip and forearm) than trabecular (spine).Hypertiroidisme was associated with bone remodelling, reduced bone density, osteoporosis and could increase fracture risk. High concentration of thyroid hormone causes osteoporosis and increase fracture risk. Changes in bone metabolism are associated with negative calcium balance, hypercalciuria and, rarely, hypercalcemia Management of hypertiroidisme affects bone density.
Keywords
References
Lawrence G.R. Physiology and Pathophysiology of Bone Remodeling. Clinical chemistry. 1999;45:1353-1358.
Setiyohadi. B. Diagnosis dan Penatalaksanaan Osteoporosis. Dalam Temu Ilmiah Reumatologi 2009.2009:117-121.
Greenspan SL, Francis. The Effect of Thyroid Hormone on Skeletal Integrity. Annals of Internal Medicine. 1999;130: 750-758.
Djokomoeljanto. Kelenjar Tiroid, Hipotiroidisme dan Hipertiroidisme dalam Buku Ajar Ilmu Penyakit Dalam. Editor Aru W Sudoyo, Setiyohaadi, B. Alwi, I. Marcellius S, Siti S. 2006; edisi IV : 1955-1965.
Sarko J. Bone and Mineral Metabolism. Emerg Med Clin. 2005;23:703-721.
Becker C. Pathophysiology and Clinical Manifestations of Osteoporosis. The best of Clinical Corner Stone. 2006;8:19-27.
Harrisons internal Medicine Osteoporosis. McGraw-Hill Companies. 348.
Sumariyono. Mekanisme Fragilitas Skeletal Pada Osteoporosis. Dalam Temu Ilmiah Reumatologi 2009.2009:128a-d .
Wexler JA, Sharretts J. Thyroid dan bone. Endocrinology and Metabolism Clinics of North America. 2007;36:673-705.
Latif R, Morshed S A, Zaidi M, Davies TF. The Thyroid-Stimulating Hormone Receptor : Impact of Thyroid Stimulating Hormone and Thyroid Stimulating Hormone Receptor Antibodies on Multimerization, cleavage and Signaling. Encrinology Metabolic Clinic of North America. 2009;38:319-341.
Sarko J. Bone and Mineral Metabolism. Emerg Med Clin. 2005;23:703-721.
Pantazi H, Papapetrou P. Changes in Parameters of Bone and Mineral Metabolism during Therapy for Hyoperthyroidism. The Journal of Clinical Endocrinology & Metabolism. 2000;85: 1099-1106.
Siddiqi A, Monson P, Wood F, Besser M, Burrin JM. Serum cytokones in Thyrotoxicosis. Jornal of Clinical Endocrine and Metabolism. 1999;84:435-439.
Bauer D C, Ettinger B, Nevit M C, stone KL. Risk for Fracture in women with Low Serum Levels of Thyroid-Stimulating Hormone. Ann Intern Med. 2001;134:561-568.
Jeanette E.C. Osteoporosis Part : Evaluation & assesment. American Family Physicians. 2001;63:897-904.
Faber J, Galloe MA. Changes in Bone Mass During Prolonged Subclinical Hyperthyroidism Due to l-thyroxine Treatment: a meta-analysis. European Journal of Endocrinology.1994;130:350-356
Siddiqi A, Burrin J M, Noonan K, James I, Wood, Price, Monson Jp. A Longitudinal Study of Markers of Bone Turnover in Graves’ Disease and Their Value in Predicting Bone Mineral Density. J Clin Endocrinol Metab. 1997;82:753-759.
Bayley A T, Harrison J, McNeill, Mernagh JR. Effect of Thurotoxicosis and its treatment on Bone Mineral and Muscle Mass. J Clin End Metab. 1980;50:916-922.
Kenneth S, DeMieri PJ. Disorder of Bone Mineral Metabolism. Clinis in Family Practice. 2002;4:525-565.
Jódar E, Muñoz-Torres M, Escobar-Jiménez F, Quesada-Charneco M, Lund del Castillo JD. Bone loss in hyperthyroid patients and in former hyperthyroid patients controlled on medical therapy: influence of aetiology and menopause.Clin Endocrinol. 1997; 47(3):279-85.
Kenneth S, DeMieri PJ. Disorder of Bone Mineral Metabolism. Clinis in Family Practice. 2002;4:525-565
Hochberg M X. Recomendations for Measurement of Bone Mineral Density and Identifying persons to be treted for Osteoporosis. Rheumatic Disease Clinicsof North America. 2006;32:681-689.
Lash RW, Nicolson JM, Velez L, Harrison RV, McCort J. Diagnosis and Management of Osteporosis. Primary care the clinic. 2009;36:181-198.
Linde J, Friss, JH. Oseoporosis in Hyperthyroidism Estimated by Photon Absorptiometry. Acta Endocrinologica, 91:437-448.
Udayakumar N, Chandrasekaran M, Rasheed M H, Suresh R V, Sivaprakash S. Evaluation of bone mineral density in Thyrotoxicosis. Singapore Med J. 2006; 47(11):947 Markers of bone turnover in hyperthyroidism and the effects of treatment. J Clin End Metab.1994;78: 955-959.
Refbacks
- There are currently no refbacks.